Alzamend Neuro (ALZN) Convertible Debt (2021)
Alzamend Neuro's (ALZN) quarterly Convertible Debt came in at $344893.0 in Q4 2021, up 1.41% quarter-over-quarter from $340098.0 in Q3 2021.
Analysis
Alzamend Neuro (ALZN) Convertible Debt (2021) Analysis & Trends
Alzamend Neuro has disclosed Convertible Debt across 1 years of filings, most recently posting $344893.0 for Q4 2021.
- In Q4 2021, Convertible Debt changed N/A year-over-year to $344893.0; the TTM figure through Oct 2021 stood at $344893.0 (changed N/A YoY), while the FY2021 annual figure was $335303.0, changed N/A from the prior year.
- Convertible Debt came in at $344893.0 for Q4 2021 at Alzamend Neuro, up from $340098.0 in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $344893.0 in Q4 2021 to a low of $335303.0 in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.51 Bn | 192.52 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.28 Bn | 176.11 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.06 Bn | 123.21 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.62 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.71 Bn | 55.52 Bn | 1.37 Bn |
| 6 | Moderna | 53.60 Bn | 48.46 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.10 Bn | 992.69 Mn |
| 8 | Biogen | 31.79 Bn | 30.50 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.11 Bn | 29.11 Bn | 1.16 Mn |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Oct 31, 2021 | 344,893.00 |
| Jul 31, 2021 | 340,098.00 |
| Apr 30, 2021 | 335,303.00 |